ELTX · Elicio Therapeutics, Inc.
Elicio Therapeutics Inc (ELTX)
What's happening
- ELTX is up 7.69% today, trading at $1.68. — Live quote
- It's trading within 3% of its 52-week low ($1.44). (Finnhub fundamentals)
- Volume today (20,355) is well below its 3-month average of 1,313,910. (Finnhub fundamentals)
- Reports earnings on 2026-11-11, 20 days away. (Finnhub earnings calendar)
- Last quarter's EPS beat estimates: $-0.43 actual vs. $-0.55 estimated (+21.5%). (Finnhub earnings history)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Key Statistics
Analyst Recommendations
Aggregate ratings for 2026-10-01 (10 analysts polled by Finnhub) — consensus count.
Performance Overview (Trailing returns vs S&P 500 benchmark)
Earnings Trends (Quarterly EPS Actual vs Estimate)
Valuation Measures & Ratios
Quarterly history (5 periods)
| Measure | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 |
|---|---|---|---|---|---|
| Market cap | $74.7M | $6.5M | $6.0M | $4.2M | $2.9M |
| P/E | -1.84 | -0.15 | -0.12 | -0.09 | -0.06 |
| Price/Book | 9.41 | -4.56 | 1.59 | 2.29 | 0.32 |
| ROE | -512.59% | 3039.39% | -1328.38% | -2608.34% | -551.47% |
| ROA | -129.86% | -192.50% | -179.22% | -162.01% | -174.47% |
Trailing-twelve-month ratios computed from SEC EDGAR quarterly figures and historical daily close prices (Alpaca). Diluted shares are derived from Net income ÷ EPS (diluted) for each quarter, not separately reported. Forward P/E/PEG unavailable (no free data source).
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-09-30. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Not investment advice — read several signals together.
Indicators None active
History limited by data provider; markers are heuristics, not signals.
Peer and sector context
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Latest SEC filing is Form 8-K, filed 2026-09-14; review it for current changes and risks. SEC EDGAR ↗
Potential concerns
- Net profit margin is -81.5%. Finnhub fundamentals ↗
- Trailing 52-week price return is -83.4%. Finnhub market metrics ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on ELTX
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 | Sep '24 | Jun '24 | Mar '24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Operating income | -$10.4M | -$10.6M | -$8.0M | -$10.1M | -$10.7M | -$10.3M | -$10.9M | -$10.2M |
| Net income | -$8.2M | -$11.8M | -$10.1M | -$10.6M | -$11.2M | -$18.8M | -$7.2M | -$11.8M |
| EPS (diluted) | $-0.43 | $-0.65 | $-0.60 | $-0.66 | $-0.87 | $-1.39 | $-0.64 | $-1.15 |
| EPS (basic) | $-0.43 | $-0.65 | $-0.60 | $-0.66 | $-0.87 | $-1.39 | $-0.64 | $-1.15 |
Balance sheet
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $31.3M | $22.7M | $25.9M | $28.3M | $29.5M | $28.1M | $28.2M | $38.4M |
| Total liabilities | $23.4M | $24.1M | $24.2M | $24.5M | $27.7M | $19.2M | $39.5M | $57.4M |
| Stockholders' equity | $7.9M | -$1.4M | $1.6M | $3.8M | $1.8M | $8.9M | -$11.3M | -$19.0M |
| Total current assets | $25.5M | $16.2M | $19.3M | $21.5M | $22.6M | $20.9M | $20.7M | $30.6M |
| Total current liabilities | $9.2M | $7.2M | $8.1M | $6.5M | $9.9M | $11.4M | $11.5M | $9.0M |
| Cash & equivalents | $23.5M | $14.9M | $18.6M | $20.6M | $22.1M | $18.4M | $17.6M | $26.0M |
| Accounts receivable | — | — | — | — | — | — | — | — |
| Other current assets | — | — | — | — | — | — | — | — |
| Property, plant & equipment | $213.0K | $249.0K | $295.0K | $328.0K | $377.0K | $430.0K | $483.0K | $523.0K |
| Other non-current assets | — | — | — | — | — | — | — | — |
| Accounts payable | $839.0K | $272.0K | $672.0K | $321.0K | $3.9M | $4.0M | $1.0M | $2.0M |
| Accrued liabilities | $7.3M | $5.9M | $6.4M | $5.2M | $5.1M | $5.8M | $8.4M | $4.9M |
| Deferred revenue (current) | — | — | $0 | $0 | $0 | $680.0K | $1.2M | $1.3M |
| Short-term debt | — | — | — | — | — | — | — | — |
| Long-term debt | $9.5M | $9.5M | $9.4M | $9.7M | $9.3M | — | $20.0M | — |
| Other non-current liabilities | — | — | — | — | — | — | — | — |
| Common stock & paid-in capital | $219.0K | $186.0K | $178.0K | $173.0K | $163.0K | $160.0K | $110.0K | $108.0K |
| Retained earnings | -$253.7M | -$245.5M | -$233.7M | -$226.0M | -$215.9M | -$205.3M | -$194.1M | -$180.1M |
| Accumulated other comprehensive income (loss) | -$126.0K | -$122.0K | -$127.0K | -$31.0K | -$70.0K | -$144.0K | -$175.0K | -$202.0K |
Cash flow
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$8.2M | -$11.6M | -$6.8M | -$11.1M | -$8.9M | -$10.1M | -$8.7M | -$7.3M |
| Investing cash flow | — | — | -$16.0K | $0 | $0 | $0 | -$45.0K | $0 |
| Financing cash flow | $16.5M | $8.0M | $4.9M | $9.6M | $11.9M | $10.3M | $227.0K | $30.8M |
| Free cash flow | — | — | -$6.8M | -$11.1M | -$8.9M | — | -$8.8M | -$7.3M |
| Capital expenditures | — | — | $16.0K | $0 | $0 | — | $45.0K | $0 |
| Share-based compensation | $935.0K | $868.0K | $772.0K | $698.0K | $710.0K | $517.0K | $464.0K | $314.0K |
| Deferred income taxes | — | — | — | — | — | — | $0 | — |
| Change in accounts payable | $627.0K | -$460.0K | $351.0K | -$3.5M | -$172.0K | $3.0M | -$946.0K | $929.0K |
| Tax withholding on stock comp | — | — | — | — | — | — | — | — |
Income statement
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Revenue | — | — | — | $2.3M | $28.3M |
| Operating income | -$37.7M | -$45.0M | -$35.7M | -$23.7M | -$39.3M |
| Net income | -$39.6M | -$51.9M | -$35.2M | -$28.2M | -$54.6M |
| EPS (diluted) | $-2.58 | $-4.25 | $-6.96 | $-89.27 | $-1.93 |
| EPS (basic) | $-2.58 | $-4.25 | $-6.96 | $-89.27 | $-1.93 |
| Operating margin | — | — | — | -$1.0K | -$139 |
| Net margin | — | — | — | -$1.2K | -$193 |
Balance sheet
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Total assets | $25.9M | $28.2M | $27.1M | $22.7M | $96.5M |
| Total liabilities | $24.2M | $39.5M | $15.8M | $13.7M | $15.0M |
| Stockholders' equity | $1.6M | -$11.3M | $11.4M | -$102.1M | -$74.5M |
| Total current assets | $19.3M | $20.7M | $16.3M | $10.7M | $91.2M |
| Total current liabilities | $8.1M | $11.5M | $9.8M | $6.9M | $11.3M |
| Cash & equivalents | $18.6M | $17.6M | $12.9M | $6.2M | $88.8M |
| Other current assets | — | — | — | $246.0K | $498.0K |
| Property, plant & equipment | $295.0K | $483.0K | $717.0K | $1.1M | $451.0K |
| Other non-current assets | — | — | — | $61.0K | $106.0K |
| Accounts payable | $672.0K | $1.0M | $4.4M | $2.8M | $4.7M |
| Accrued liabilities | $6.4M | $8.4M | $3.8M | $1.9M | $3.2M |
| Deferred revenue (current) | $0 | $1.2M | $694.0K | $1.4M | $2.3M |
| Short-term debt | — | — | — | — | $0 |
| Long-term debt | $9.4M | $20.0M | — | — | $0 |
| Common stock & paid-in capital | $178.0K | $110.0K | $96.0K | $3.0K | $300.0K |
| Retained earnings | -$233.7M | -$194.1M | -$142.2M | -$107.0M | -$215.1M |
| Accumulated other comprehensive income (loss) | -$127.0K | -$175.0K | -$197.0K | $0 | -$103.0K |
Cash flow
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Operating cash flow | -$37.0M | -$37.1M | -$32.7M | -$22.2M | -$52.6M |
| Investing cash flow | -$16.0K | -$84.0K | -$32.0K | -$654.0K | -$382.0K |
| Financing cash flow | $36.7M | $42.3M | $38.6M | $21.2M | $107.2M |
| Free cash flow | -$37.0M | -$37.2M | -$32.8M | -$22.8M | -$53.0M |
| Capital expenditures | $16.0K | $87.0K | $66.0K | $654.0K | $382.0K |
| Share-based compensation | $2.7M | $1.5M | $1.2M | $579.0K | $12.0M |
| Deferred income taxes | — | $0 | $0 | $0 | $0 |
| Change in accounts payable | -$366.0K | -$3.3M | $23.0K | $1.1M | -$866.0K |
| Tax withholding on stock comp | — | — | — | $0 | $2.5M |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding ELTX as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR Form 4 filings · checked 25 most recent filings · covers 2025-12-09 to 2026-02-02
Recent transactions
- Most recent: Connelly Robert (CEO, President and Director) — Grant / award of 73,600 shares on 2026-02-02.
Deterministic template sentences filled in from the SEC Form 4 figures in the tables below -- not an AI-written summary, no live model call.
Insider purchases & sales, last 6 months
Counts only open-market purchases (code P) and sales (code S) — grants, option exercises, tax withholding, and gifts are excluded since they aren't a market buy/sell decision.
Insider roster
| Name | Title | Most Recent Transaction | Date | Shares |
|---|---|---|---|---|
| Connelly Robert | CEO, President and Director | Grant / award | 2026-02-02 | 73,600 |
| Shah Preetam | See Remarks | Grant / award | 2026-02-02 | 24,000 |
| DeMuth Peter | Chief Scientific Officer | Grant / award | 2026-02-02 | 20,800 |
| Haqq Christopher | See Remarks | Grant / award | 2026-02-02 | 25,400 |
Recent transactions
| Date | Insider | Title | Transaction | Shares | Price |
|---|---|---|---|---|---|
| 2026-02-02 | Connelly Robert | CEO, President and Director | Grant / award | 73,600 | $0.00 |
| 2026-02-02 | Shah Preetam | See Remarks | Grant / award | 24,000 | $0.00 |
| 2026-02-02 | DeMuth Peter | Chief Scientific Officer | Grant / award | 20,800 | $0.00 |
| 2026-02-02 | Haqq Christopher | See Remarks | Grant / award | 25,400 | $0.00 |
| 2025-12-09 | DeMuth Peter | Chief Scientific Officer | Option exercise | 362 | $4.41 |
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-10-22 08:39 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-09-14 | 8-K | 2026-09-14 | View on SEC.gov → |
| 2026-09-02 | 4 | 2026-08-31 | View on SEC.gov → |
| 2026-09-02 | 4 | 2026-08-31 | View on SEC.gov → |
| 2026-09-02 | 4 | 2026-08-31 | View on SEC.gov → |
| 2026-09-02 | 4 | 2026-08-31 | View on SEC.gov → |
| 2026-09-02 | 4 | 2026-08-31 | View on SEC.gov → |
| 2026-09-02 | 4 | 2026-08-31 | View on SEC.gov → |
| 2026-09-02 | 4 | 2026-08-31 | View on SEC.gov → |
| 2026-08-13 | 10-Q | 2026-06-30 | View on SEC.gov → |
| 2026-08-13 | 8-K | 2026-08-13 | View on SEC.gov → |
| 2026-07-17 | 4 | 2026-07-16 | View on SEC.gov → |
| 2026-07-17 | 4 | 2026-07-16 | View on SEC.gov → |
Recent news
Headlines about ELTX (Elicio Therapeutics, Inc.). Links open the publisher — we don’t host full articles.
-
Elicio Therapeutics Announces Late-Breaking Phase 2 AMPLIFY-7P Data Selected for Proffered Paper Oral Presentation at ESMO Congress 2026
Yahoo Finance · 2026-09-24 -
Elicio Therapeutics to Participate at the H.C. Wainwright 28th Annual Global Investment Conference
Yahoo Finance · 2026-08-31 -
Elicio Therapeutics to Participate at the Wells Fargo 21st Annual Healthcare Conference
Yahoo Finance · 2026-08-24 -
Elicio Therapeutics GAAP EPS of -$0.43 beats by $0.11
Seeking Alpha · 2026-08-13 -
Elicio Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Updates
Yahoo Finance · 2026-08-13 -
Elicio Therapeutics Announces Closing of $15 Million Registered Direct Offering
Yahoo Finance · 2026-07-06 -
Elicio Therapeutics Announces Pricing of $15 Million Registered Direct Offering
Yahoo Finance · 2026-07-02 -
Elicio Therapeutics Added to Russell 2000® and Russell 3000® Indexes
Yahoo Finance · 2026-06-29
No headlines in this category right now — try “All”.